All In Biotech

Drug Trial Radar · NCT07733765

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE ALOPECIA AREATA

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

336

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Apr 26, 2028

Study completion Apr 26, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA). This study is seeking participants who are * 12 years or older (if permitted by the local IRB/EC and local regulatory health authority) * have AA with patchy hair loss. The current episode of hair loss has lasted for 6 months or longer but 10 years or less * do not have any other diseases or conditions affecting hair loss. Participants will have a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo. The placebo looks like the study medicine but does not contain any active ingredients. Participants will not know what you have been assigned to receive. They will take ritlecitinib or placebo once daily by mouth at home for 24 weeks (6 months). After 24 weeks, the assigned treatment may stay the same or be changed to ritlecitinib 50 mg or 100 mg. This change will depend on how participants' alopecia areata responds to the treatment. Participants will receive the newly assigned treatment for another 23 weeks. About 4 weeks after the last dose, there will be a follow-up visit. At this visit, the team will check on your health. Participants will take part in this study for about 57 weeks. During this time, they will have study visits at the study clinic. Some study checks will be done by phone. We will compare the experiences of people receiving ritlecitinib to those of people who do not. This will help us determine if ritlecitinib is safe and effective.

Conditions

  • Alopecia Areata

Interventions

  • Ritlecitinib 100 mgDrug

    100 mg capsule taken orally once daily

  • Ritlecitinib 50 mgDrug

    50 mg capsule taken orally once daily

  • PlaceboOther

    Capsule matching either 50mg or 100 mg ritlecitinib capsule taken orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placeboTime frame: Week 24

Locations

38 sites in 5 countries. Site status is shown where the registry gives one.

  • California Dermatology & Clinical Research Institute

    Encinitas, California · Recruiting

  • Skin Research of South Florida

    Miami, Florida · Recruiting

  • Endeavor Health

    Skokie, Illinois · Not yet recruiting

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana · Recruiting

  • University of Iowa

    Iowa City, Iowa · Not yet recruiting

  • Cutaneous Translational Research Program, Johns Hopkins University School of Medicine

    Baltimore, Maryland · Not yet recruiting

  • Johns Hopkins Hospital Investigational Drug Services (IDS) Pharmacy

    Baltimore, Maryland · Not yet recruiting

  • Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)

    Boston, Massachusetts · Recruiting

  • Revival Research Institute, LLC

    Troy, Michigan · Recruiting

  • Clinical and Translational Research Center (CTRC)

    Chapel Hill, North Carolina · Recruiting

  • UNC Dermatology and Skin Cancer Center

    Chapel Hill, North Carolina · Recruiting

  • Audiology & Hearing Services

    Charlotte, North Carolina · Recruiting

  • Carolinas Imaging Service

    Charlotte, North Carolina · Recruiting

  • Darst Dermatology

    Charlotte, North Carolina · Recruiting

  • Bexley Dermatology Research

    Bexley, Ohio · Recruiting

  • NW Dermatology Institute

    Portland, Oregon · Recruiting

  • Dermatology Associates of Plymouth Meeting

    Plymouth Meeting, Pennsylvania · Recruiting

  • Center for Clinical Studies, LTD. LLP

    Houston, Texas · Recruiting

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas · Recruiting

  • Dermatology Specialists of Spokane

    Spokane, Washington · Not yet recruiting

  • Principle Research Solutions

    Spokane, Washington · Not yet recruiting

  • Wiseman Dermatology Research Inc.

    Winnipeg, Manitoba, Canada · Recruiting

  • The Centre for Clinical Trials

    Oakville, Ontario, Canada · Recruiting

  • Research Toronto

    Toronto, Ontario, Canada · Recruiting

  • Centre de Recherche Saint-Louis (Montréal)

    Montreal, Quebec, Canada · Recruiting

  • Centre de Recherche Saint-Louis (Québec)

    Québec, Quebec, Canada · Recruiting

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Niigata University Medical & Dental Hospital

    Niigata, Japan · Recruiting

  • Osaka Metropolitan University Hospital

    Osaka, Japan · Recruiting

  • Hospital of the University of Occupational and Environmental Health, Japan

    Kitakyushu-shi, Fukuoka, Japan · Recruiting

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, Japan · Recruiting

  • Juntendo Tokyo Koto Geriatric Medical Center

    Koto-ku, Tokyo, Japan · Recruiting

  • Kyorin University Hospital

    Mitaka, Tokyo, Japan · Recruiting

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Jeonbuk National University Hospital

    Jeonju, Jeonrabugdo,, South Korea · Not yet recruiting

  • Kyung Hee University Hospital at Gangdong

    Seoul, Seoul-teukbyeolsi [seoul], South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.